Back | Next |
home / stock / rprx / rprx message board
Subject | By | Source | When |
---|---|---|---|
https://www.otcmarkets.com/stock/$RPRX | mick | investorshub | 01/02/2022 10:13:39 PM |
https://www.otcmarkets.com/stock/$RPRX | mick | investorshub | 12/11/2021 10:11:06 PM |
Royalty Pharma PLC ($RPRX) | mick | investorshub | 11/06/2021 4:41:00 PM |
whytestocks: $RPRX News Article - Royalty Pharma Declares Fourth-Quarter 2021 Dividend | whytestocks | investorshangout | 10/15/2021 4:30:53 PM |
Royalty Pharma PLC ($RPRX) | mick | investorshub | 10/08/2021 3:15:46 PM |
Royalty Pharma PLC ($RPRX) | mick | investorshub | 09/22/2021 11:36:21 PM |
Royalty Pharma PLC ($RPRX) | mick | investorshub | 08/14/2021 4:55:22 PM |
Royalty Pharma PLC ($RPRX) | mick | investorshub | 07/11/2021 3:58:14 AM |
Royalty Pharma PLC ($RPRX) | mick | investorshub | 07/09/2021 7:48:50 PM |
Royalty Pharma PLC ($RPRX) | mick | investorshub | 05/26/2021 4:09:02 PM |
www.stockscores.com/chart.asp?TickerSymbol=$RPRX&TimeRange=180&Interval=d& | mick | investorshub | 05/03/2021 12:36:09 AM |
Royalty Pharma PLC ($RPRX) | mick | investorshub | 05/02/2021 12:06:12 AM |
Royalty Pharma PLC ($RPRX) | mick | investorshub | 04/18/2021 4:22:30 PM |
Royalty Pharma PLC ($RPRX) | mick | investorshub | 02/20/2021 11:36:35 PM |
https://otcbb.swingtradebot.com/equities/$RPRX | mick | investorshub | 01/31/2021 8:50:26 PM |
whytestocks: $RPRX News Article - Royalty Pharma to Announce Fourth-Quarter 2020 Financial Results o | whytestocks | investorshangout | 01/22/2021 7:20:48 PM |
https://pennystocks.news/otc/?symbol=$RPRX | mick | investorshub | 01/03/2021 4:51:38 PM |
whytestocks: $RPRX News Article - Royalty Pharma Announces Charitable Gifts to Support COVID-19 Rese | whytestocks | investorshangout | 12/22/2020 6:55:48 PM |
Royalty Pharma PLC ($RPRX) | mick | investorshub | 12/07/2020 5:13:04 PM |
Royalty Pharma PLC ($RPRX) | mick | investorshub | 11/25/2020 1:00:41 AM |
News, Short Squeeze, Breakout and More Instantly...
Tuesday, Agios Pharmaceuticals Inc (NASDAQ:AGIO) agreed to sell its rights to its 15% royalty on potential U.S. net sales ...
Vorasidenib, if approved, would be the first targeted therapy in IDH-mutant glioma, a progressive and incurable brain tumor Pivotal Phase 3 clini...
Vorasidenib, if approved, would be the first targeted therapy in IDH-mutant glioma, a progressive and incurable brain tumor Pivotal Phase 3 clinical study of vorasidenib demonstrated unprecedented efficacy and tolerability; vorasidenib granted priority review with PDUFA date of August 20,...